Request Trial
designer491
designer491 / iStockphoto.com
18 December 2017Americas

Oxford Immunotec settles with Qiagen, signs $27.5m licence

UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Skinny labels, big stakes: SCOTUS lines up the case of the year
21 January 2026   The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.
Americas
$5.4bn medtech leader fails to bury a rival's patent
19 January 2026   An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.
Americas
ITC to probe Oura Ring after Samsung retaliates, seeking import ban
15 January 2026   The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

More features

Skinny labels, big stakes: SCOTUS lines up the case of the year
Chinese biotech strikes billion dollar deal in nextgen cancer race
$5.4bn medtech leader fails to bury a rival's patent
Senior four-partner team leaves A&O Shearman
Final call: Who are the world’s best in-house counsel?
ITC to probe Oura Ring after Samsung retaliates, seeking import ban
Speciality pharma firm stumbles on bid to enforce Belbuca ruling
Italian medtech startup beats larger US rival in UPC dispute